Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SYK Stock Forecast 2026-2027
$331.20
Current Price
$119.25B
Market Cap
Buy 22
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to SYK Price Targets
+40.4%
To High Target of $465.00
+15.9%
To Median Target of $384.00
-4.9%
To Low Target of $315.00
SYK Price Momentum
+0.4%
1 Week Change
+7.6%
1 Month Change
-14.9%
1 Year Change
-5.8%
Year-to-Date Change
-18.2%
From 52W High of $404.87
+17.9%
From 52W Low of $281.00
📊 TOP ANALYST CALLS
Did SYK Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Stryker is one of their latest high-conviction picks.
Latest SYK Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, SYK has a bullish consensus with a median price target of $384.00 (ranging from $315.00 to $465.00). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $331.20, the median forecast implies a 15.9% upside. This outlook is supported by 22 Buy, 6 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SYK Analyst Ratings
22
Buy
6
Hold
0
Sell
SYK Price Target Range
Low
$315.00
Average
$384.00
High
$465.00
Current: $331.20
Latest SYK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SYK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 9, 2026 | BMO Capital | Outperform | Initiates | $369.00 | |
| Jul 6, 2026 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $350.00 |
| Jun 5, 2026 | Leerink Partners | Outperform | Maintains | $N/A | |
| May 4, 2026 | Truist Securities | Hold | Reiterates | $N/A | |
| May 4, 2026 | Barclays | Overweight | Maintains | $N/A | |
| May 1, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| May 1, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| May 1, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| May 1, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| May 1, 2026 | Needham | Buy | Maintains | $N/A | |
| May 1, 2026 | BTIG | Buy | Maintains | $N/A | |
| Apr 15, 2026 | Truist Securities | Hold | Maintains | $N/A | |
| Apr 14, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Apr 13, 2026 | Leerink Partners | Outperform | Initiates | $N/A | |
| Apr 9, 2026 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Apr 7, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Apr 6, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Mar 17, 2026 | UBS | Neutral | Maintains | $N/A | |
| Feb 24, 2026 | UBS | Neutral | Maintains | $N/A | |
| Feb 2, 2026 | Barclays | Overweight | Maintains | $N/A |
Stryker Corporation (SYK) Competitors
The following stocks are similar to Stryker based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Stryker Corporation (SYK) Financial Data
Stryker Corporation has a market capitalization of $119.25B with a P/E ratio of 38.6x. The company generates $25.27B in trailing twelve-month revenue with a 13.2% profit margin.
Revenue growth is +2.6% quarter-over-quarter, while maintaining an operating margin of +17.8% and return on equity of +15.2%.
Valuation Metrics
Market Cap
$119.25B
Enterprise Value
$138.69B
P/E Ratio
38.6x
PEG Ratio
2.8x
Price/Sales
5.1x
Growth & Margins
Revenue Growth (YoY)
+2.6%
Gross Margin
+63.3%
Operating Margin
+17.8%
Net Margin
+13.2%
EPS Growth
+13.9%
Financial Health
Cash/Price Ratio
+2.3%
Current Ratio
2.1x
Debt/Equity
66.3x
ROE
+15.2%
ROA
+7.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Stryker Corporation (SYK) Business Model
About Stryker Corporation
What They Do
Medical technology improving patient outcomes globally.
Business Model
The company generates revenue through its two primary segments: MedSurg and Neurotechnology, which includes surgical equipment and neurology products, and Orthopaedics and Spine, focusing on joint replacements and spinal implants. By providing advanced medical devices and solutions, Stryker serves hospitals, physicians, and healthcare institutions, facilitating better healthcare delivery.
Additional Information
Founded in 1941 and headquartered in Portage, Michigan, Stryker Corporation is a key player in the global medtech industry, known for its innovative products that enhance surgical precision and patient recovery.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
56,000
CEO
Mr. Kevin A. Lobo
Country
United States
IPO Year
1988
Website
www.stryker.comStryker Corporation (SYK) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
ISRG to Report Q2 Results Next Week: Should You Buy the Stock Now?
ISRG is set to report Q2 results on July 16, with sales and EPS expected to rise, while investors weigh margin pressure against strong adoption of da Vinci 5.
Jul 10, 2026
By Indrajit Bandyopadhyay
Analyst Blog
Beyond Automotive: Healthcare Automation Drives the Next Leg for Robotics ETFs
Rising use of automation in healthcare is reshaping robotics ETFs as med-tech innovators gain prominence.
Jul 08, 2026
By Aparajita Dutta
ETF News and Commentary
ICUI vs. SYK: Which Stock Should Value Investors Buy Now?
ICUI vs. SYK: Which Stock Is the Better Value Option?
Jul 08, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Stryker has launched the Mako RPS, a handheld robotic system for total knee replacements, expanding the Mako platform into a new segment of the orthopedic market.
Why It Matters
Stryker's launch of Mako Handheld Robotics enhances its product offerings, potentially increasing market share and revenue in orthopedic surgery, positively impacting investor confidence and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Booking Holdings, Alphabet, and six other companies are underperforming their sectors, despite rising earnings expectations, indicating potential upside in the upcoming second-quarter earnings season.
Why It Matters
Underperforming stocks with improving earnings expectations may present buying opportunities, signaling potential gains as second-quarter results are released.
Source: Barrons
Market Sentiment:
Positive
Quick Summary
Stryker Corporation (SYK) trades at a 13% discount to fair value with a forward P/E of 20.1. EPS is expected to grow 11.2% annually through 2028, supporting dividend growth.
Why It Matters
Stryker's strong growth prospects, undervalued stock, and solid EPS growth forecast indicate potential for capital appreciation and reliable dividends, appealing to growth-focused investors.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Stryker had a rare Q1 miss due to a temporary cyber disruption, but full-year guidance remains unchanged. Demand is healthy, making current valuations more attractive for investors.
Why It Matters
Stryker's Q1 miss due to a cyber disruption is temporary, with unchanged guidance and healthy demand. This presents a potential buying opportunity despite its current high valuation.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Increasing automation in healthcare is enhancing the significance of robotics ETFs, with medical technology innovators emerging as key players.
Why It Matters
Rising automation in healthcare boosts robotics ETFs, signaling growth in med-tech. This trend could lead to increased investment opportunities and potential returns in the sector.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investors in the Medical - Products sector may consider ICU Medical (ICUI) and Stryker (SYK) for potential value opportunities.
Why It Matters
The comparison of ICU Medical and Stryker highlights potential investment opportunities in the Medical - Products sector, influencing portfolio decisions based on value assessments.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About SYK Stock
What is Stryker Corporation's (SYK) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Stryker Corporation (SYK) has a median price target of $384.00. The highest price target is $465.00 and the lowest is $315.00.
Is SYK stock a good investment in 2027?
According to current analyst ratings, SYK has 22 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $331.20. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SYK stock?
Wall Street analysts predict SYK stock could reach $384.00 in the next 12 months. This represents a 15.9% increase from the current price of $331.20. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Stryker Corporation's business model?
The company generates revenue through its two primary segments: MedSurg and Neurotechnology, which includes surgical equipment and neurology products, and Orthopaedics and Spine, focusing on joint replacements and spinal implants. By providing advanced medical devices and solutions, Stryker serves hospitals, physicians, and healthcare institutions, facilitating better healthcare delivery.
What is the highest forecasted price for SYK Stryker Corporation?
The highest price target for SYK is $465.00 from at , which represents a 40.4% increase from the current price of $331.20.
What is the lowest forecasted price for SYK Stryker Corporation?
The lowest price target for SYK is $315.00 from at , which represents a -4.9% decrease from the current price of $331.20.
What is the overall SYK consensus from analysts for Stryker Corporation?
The overall analyst consensus for SYK is bullish. Out of 3 Wall Street analysts, 22 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $384.00.
How accurate are SYK stock price projections?
Stock price projections, including those for Stryker Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 3:19 AM UTC